Principal Financial Group Inc. Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Principal Financial Group increased its stake in Vertex by 2.1% to 415,100 shares (worth about $188.2 million), and overall institutional investors own roughly 90.96% of the stock.
• Vertex beat Q1 EPS ($4.47 vs. $4.24) with revenue growth driven by new cystic fibrosis therapies, while management reiterated full‑year guidance of about $13.0–$13.1 billion and analysts maintain a consensus "Moderate Buy" with an average target near $554.83.
• Notable insider selling occurred recently—insiders sold 81,853 shares (~$38.48 million) in the last quarter—which could weigh on near‑term sentiment despite the operational beats.

Principal Financial Group Inc. increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 415,100 shares of the pharmaceutical company's stock after purchasing an additional 8,600 shares during the period. Principal Financial Group Inc. owned 0.16% of Vertex Pharmaceuticals worth $188,190,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in VRTX. Colonial Trust Co SC raised its holdings in shares of Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 38 shares in the last quarter. Eagle Bay Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $29,000. Ares Financial Consulting LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $33,000. Financial Network Wealth Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 50.9% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company's stock worth $34,000 after acquiring an additional 29 shares in the last quarter. Finally, Archer Investment Corp raised its holdings in shares of Vertex Pharmaceuticals by 89.7% during the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company's stock worth $34,000 after acquiring an additional 35 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat on EPS and showed revenue growth driven by product sales; management highlighted broad portfolio strength and pipeline progress, supporting longer‑term growth thesis. Business Wire: Vertex Reports First Quarter 2026 Financial Results
• Positive Sentiment: Sales of new CF therapies and other recently launched products accelerated, contributing materially to product revenue growth and suggesting multiple near‑term commercial growth engines. Reuters: Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Neutral Sentiment: Vertex reiterated full‑year 2026 revenue guidance (~$13.0B–$13.1B), roughly in line with consensus — supportive for guidance stability but not a clear upside catalyst. Investor Slide Deck / Press Release (Q1 2026)
• Neutral Sentiment: Analysts revised models and price targets after the Q1 release — many maintained Outperform/Buy views but trimmed targets, reflecting mixed near‑term readings despite constructive longer‑term views. Benzinga: These Analysts Revise Their Forecasts On Vertex After Q1 Earnings
• Negative Sentiment: Insider selling was reported this week (EVP Joy Liu sold 1,104 shares; director Sangeeta Bhatia sold 318 shares). Trades were executed under 10b5‑1 plans, but active insider sales can weigh on sentiment. SEC Form 4 (Joy Liu) SEC Form 4 (Sangeeta Bhatia)
• Negative Sentiment: Shares dipped after the mixed report (EPS/revenue beats but some metrics and commentary left investors cautious), prompting near‑term profit‑taking and PT trims. Yahoo Finance: Vertex Dips On Mixed First‑Quarter Report

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VRTX. Royal Bank Of Canada lifted their price objective on shares of Vertex Pharmaceuticals from $541.00 to $543.00 and gave the stock an "outperform" rating in a research note on Tuesday. HC Wainwright boosted their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a "buy" rating in a report on Tuesday, March 10th. Scotiabank boosted their target price on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an "outperform" rating in a report on Friday, February 13th. Bank of America boosted their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a "buy" rating in a report on Tuesday, March 10th. Finally, Jefferies Financial Group initiated coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, March 10th. They issued a "buy" rating and a $580.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $554.83.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $424.36 on Wednesday. The company has a market cap of $107.94 billion, a P/E ratio of 25.17, a P/E/G ratio of 1.87 and a beta of 0.30. The business's 50 day moving average price is $452.77 and its 200-day moving average price is $449.59. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.23. The firm had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 24.41% and a net margin of 35.51%.The company's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.06 EPS. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current year.

Insider Activity

In other news, EVP Jonathan Biller sold 1,925 shares of the business's stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $886,327.75. Following the transaction, the executive vice president owned 20,819 shares of the company's stock, valued at approximately $9,585,692.17. The trade was a 8.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Duncan Mckechnie sold 4,910 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the transaction, the executive vice president directly owned 17,559 shares in the company, valued at approximately $8,562,646.35. This represents a 21.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 81,853 shares of company stock worth $38,479,135. Company insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.